![](https://cdn.statically.io/img/www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F0%2F9%2F4%2F0%2F47910490-9-eng-GB%2FCropped-1719843153photo_SXM2024070100014519.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms)
TOKYO -- Asian investment fund MBK Partners will buy Japan's Alinamin Pharmaceutical, a maker of supplements and nonprescription drugs, from Blackstone Group for an estimated 350 billion yen ($2.2 billion), Nikkei learned Tuesday.
MBK, which has experience in consumer goods with such acquisitions as Godiva's Asia-Pacific business and jewelry maker Tasaki, aims to use this know-how to boost Alinamin's value.